Bayer and Arvinas to Collaborate on Human PROTAC Therapies and Launch a Separate Joint Venture to…
Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...
Read More...
